Lyndra Therapeutics, a biopharmaceutical company focused on the development of long-acting oral therapies, has entered into a strategic collaboration with Thermo Fisher Scientific to utilise its global clinical research and commercial manufacturing services for its long-acting oral therapies.

Through the collaboration, the companies will leverage Thermo Fisher’s Accelerator Drug Development services, 360° Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) drug development solutions. Accelerator Drug Development provides a customisable suite of manufacturing, clinical research and clinical supply chain services for emerging biotechs and large pharmaceutical companies at every stage from pre-clinical to commercialisation.

Lyndra intends to leverage Thermo Fisher’s complete and advanced pharmaceutical manufacturing capabilities in Ohio, US, in addition to Lyndra’s LYNX drug delivery platform commercial line to manufacture materials at scale.